GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (FRA:1BT) » Definitions » Deferred Policy Acquisition Costs

Enlivex Therapeutics (FRA:1BT) Deferred Policy Acquisition Costs


View and export this data going back to 2015. Start your Free Trial

What is Enlivex Therapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Enlivex Therapeutics (FRA:1BT) Business Description

Industry
Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.